Scienture Holdings, Inc.
No enriched coverage for $SCNX in the last 7 days.
No SEC Form 4 filings for $SCNX in the last 30 days.
See all $SCNX insider activity →Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base Q2 2026 Operat
Scienture Holdings (NASDAQ: SCNX) reported Q2 2026 results: revenue rose about 510% sequentially to $343,639 from $56,325 in Q1. Q2 gross margin was about 97.7%. Operating loss improved about 48% to ~$2.7M and net loss narrowed about 58% to ~$2.8M. The company began commercial launch of REZENOPY and cited USPTO patent grants and expanded payer coverage.
Scienture (NASDAQ:SCNX) says it has commercially launched REZENOPY, a 10 mg naloxone hydrochloride nasal spray, after fulfilling initial U.S. wholesaler purchase orders and starting nationwide distribution. The company cites IQVIA data for a $143 million U.S. naloxone market (9.8 million units) and says payer coverage could exceed 100 million lives via GPO access to 5,000+ facilities. No revenue guidance was provided.
Recent SCNX coverage spans financial news, market movers and earnings.
Strong top-line growth and high margins may trigger price appreciation.
The print suggests early commercial traction (REZENOPY launch, payer coverage gains) alongside improving cost discipline and cash.
The launch shifts REZENOPY from regulatory readiness to revenue generation, making near-term adoption and sell-through the key driver for SCNX.
The pre-market jump is tied to a concrete commercialization milestone for REZENOPY, implying near-term distribution ramp risk-on.
Commercial inventory readiness and imminent wholesale shipments are a near-term execution catalyst for REZENOPY commercialization, supporting sentiment and potential demand visibility.
alphai scores every news story that mentions SCNX with an AI model for sentiment and relevance, and aggregates insider trades from Scienture Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base Q2 2026 Operat
2 min readScienture Holdings (NASDAQ: SCNX) reported Q2 2026 results: revenue rose about 510% sequentially to $343,639 from $56,325 in Q1. Q2 gross margin was about 97.7%. Operating loss improved about 48% to ~$2.7M and net loss narrowed about 58% to ~$2.8M. The company began commercial launch of REZENOPY and cited USPTO patent grants and expanded payer coverage.
4 min readScienture (NASDAQ:SCNX) says it has commercially launched REZENOPY, a 10 mg naloxone hydrochloride nasal spray, after fulfilling initial U.S. wholesaler purchase orders and starting nationwide distribution. The company cites IQVIA data for a $143 million U.S. naloxone market (9.8 million units) and says payer coverage could exceed 100 million lives via GPO access to 5,000+ facilities. No revenue guidance was provided.
5 min readScienture Holdings (NASDAQ:SCNX) shares rose about 21% pre-market to $0.4046 after the company said it completed manufacturing of commercial launch inventory for REZENOPY (naloxone HCl) 10 mg nasal spray. Shipments to U.S. wholesalers are expected later this month, with retail availability in August. SCNX closed Thursday at $0.33.
4 min readScienture Holdings (SCNX) said it completed manufacturing commercial launch inventory for REZENOPY naloxone nasal spray 10 mg and will start shipments to U.S. wholesalers in July, with broad availability expected in August. The company cited IQVIA data valuing the U.S. naloxone market at about $144 million annually and said payer access could cover over 100 million lives.
3 min readScienture Holdings (NASDAQ: SCNX) said the U.S. Patent and Trademark Office granted U.S. Patent No. 12,622,903 B2 covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026 and expiring Feb. 5, 2041. The patent was issued to Summit Biosciences, a subsidiary of Kindeva. Scienture’s subsidiary has exclusive U.S. commercialization rights; REZENOPY™ was FDA-approved April 19, 2024. IQVIA data cited: ~$141M annual U.S. naloxone sales and 9.4M units (MAT Jan 2026).
4 min readReports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to ...
3 min readOn Thursday, Scienture Holdings, Inc. ( NASDAQ:SCNX ) reported financial results for the third quarter. Net revenue increased from approximately $65 thousand to $590 thousand, while gross profit increased from roughly $4 thousand to $575 thousand.
2 min readScienture Holdings, Inc. ( NASDAQ:SCNX ) announced on Tuesday that Arbli ( losartan potassium ) Oral Suspension, 10 mg/mL, has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans.
3 min readMajor U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average up 0.3% at 46,734.61, the S&P 500 advancing nearly 0.6% to 6,738.44, and the Nasdaq climbing about 0.9% to 22,941.79. These are the top stocks that gained the attention of retail traders and investors through the ...
4 min read
